“After the launch of the drugs on Monday, the demand for the drug may be very excessive as plenty of sufferers and their family are sharing constructive experiences,” authorities sources mentioned.
However, due to the restricted production capability, many sufferers haven’t been in a position to get the drugs regardless of a prescription from docs, they mentioned.
In view of the state of affairs, we’re contemplating permitting 3-4 more firms to produce the drug utilizing the DRDO patent for the drug, the sources mentioned.
In the primary batch, producers had provided solely 10,000 sachets and the provision is probably going to enhance solely round mid-June.
From the primary batch of the drugs, satchets have been distributed to the All India Institute of Medical Sciences (AIIMS) and the Director-General of the Armed Forces Medical Services whereas some have been saved as reserve.
2-DG has been developed by DRDO’s Institute of Nuclear Medicine and Allied Sciences (INMAS), in collaboration with Dr Reddy’s Laboratories, Hyderabad. Clinical trial outcomes have proven that this molecule helps in the quicker restoration of hospitalized sufferers and reduces supplemental oxygen dependence.
A better proportion of sufferers handled with 2-DG have proven RT-PCR unfavourable conversion in COVID sufferers. The drug will likely be of immense profit to the folks affected by COVID in the continued pandemic.